Annuncio pubblicitario
Italia Markets open in 6 hrs 54 mins
  • Dow Jones

    38.989,83
    -97,57 (-0,25%)
     
  • Nasdaq

    16.207,51
    -67,39 (-0,41%)
     
  • Nikkei 225

    39.907,86
    -2,94 (-0,01%)
     
  • EUR/USD

    1,0855
    -0,0004 (-0,0326%)
     
  • BTC-EUR

    62.860,06
    +4.207,19 (+7,17%)
     
  • CMC Crypto 200

    885,54
    0,00 (0,00%)
     
  • HANG SENG

    16.595,97
    +6,57 (+0,04%)
     
  • S&P 500

    5.130,95
    -6,13 (-0,12%)
     

Change in Orion Group's Half-Year Financial Report 2024 publication date

Orion Oyj
Orion Oyj

ORION CORPORATION
STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR    
20 SEPTEMBER 2023 at 12.00 noon EEST              

Change in Orion Group's Half-Year Financial Report 2024 publication date 

Orion Corporation changes the publication date of its Half-Year Financial Report January–June 2024. The new publication date is Thursday 8 August 2024 (was previously Thursday 18 July 2024). The financial calendar will otherwise remain unchanged.

The publication dates of the Financial Statement Release for 2023, and Interim Reports and the Half-Year Financial Report in 2024 are as follows:

Financial Statement Release for 2023
Interim Report January-March 2024 
Half-Year Financial Report January-June 2024
Interim Report January-September 2024

 

Tuesday, 13 February 2024
Thursday, 25 April 2024
Thursday, 8 August 2024
Tuesday, 29 October 2024

Orion Corporation

Liisa Hurme

President and CEO

   

Olli Huotari

SVP, Corporate Functions

 


Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.